Should You Buy Phibro Animal Health Corporation Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Phibro Animal Health Corporation (PAHC) scores a robust 8.7/10 on our 32-signal Quality of Company framework. At the current market price of $35.03 and a $1.4B market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.
The short answer: 6 of 11 CirclFi valuation models project upside for Phibro Animal Health Corporation (PAHC) at $35.03 — the model consensus leans bullish, with a Quality Score of 8.7/10 and Value-Trap risk of 16/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Phibro Animal Health Corporation (PAHC) in 2026?
What Is the Bull Case vs the Bear Case for Phibro Animal Health Corporation (PAHC)?
| Bull case — $80.71 target (+130.4%) | Bear case — $1.05 target (-97.0%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Phibro Animal Health Corporation's quality score of 8.7/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation. | According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model sees the stock as overvalued with a fair value of $1.05 (-97.0%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $80.71 (+130.4%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +227.4% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| Industry tailwind: orphan drug designation could provide meaningful support for Phibro Animal Health Corporation's revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. | Industry headwind: patent expiration revenue loss represents a meaningful risk for Phibro Animal Health Corporation and its Drug Manufacturers - Specialty & Generic peers. |
How Does PAHC Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: COLL · ALKS · RDY · HLN · ELTP · ETST · TEVA · BIOA · KOAN · UTHR · AMPH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like PAHC on Quality?
Closest companies to PAHC’s Quality of Company score of 8.7/10, across all industries.
- EW — Edwards Lifesciences Corporation (QOC 8.7) · analysis
- YOU — Clear Secure, Inc. (QOC 8.7) · analysis
- EQT — EQT Corporation (QOC 8.7) · analysis
- KRT — Karat Packaging Inc. (QOC 8.7) · analysis
- SIG — Signet Jewelers Limited (QOC 8.7) · analysis
- IRDM — Iridium Communications Inc. (QOC 8.7) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does PAHC Appear In?
So Is Phibro Animal Health Corporation (PAHC) Worth Buying in 2026?
Phibro Animal Health Corporation at $35.03 is a genuine coin-flip in our framework. The 6–5 bull-bear split across 11 models, +227.4% model spread, and median fair value of $37.23 (+6.3% vs price) argue for a watchlist position rather than a high-conviction bet. Quality at 8.7/10 adds some comfort to the mix.
These are quantitative model outputs, not investment recommendations. Phibro Animal Health Corporation's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About PAHC Stock?
Should I buy PAHC stock right now?
Based on CirclFi's multi-model analysis, 6 of 11 models see upside for PAHC at $35.03. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 8.7/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Phibro Animal Health Corporation?
Key risks include: wide model disagreement (7574% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does PAHC compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, PAHC holds a Quality Score of 8.7/10. Comparable companies include COLL (QOC 8.8), ALKS (QOC 8.6), RDY (QOC 8.8). The relative ranking helps investors identify whether PAHC offers better fundamental quality than alternatives in the same sector.
Is PAHC a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. PAHC's Quality Score of 8.7/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy PAHC at?
CirclFi does not provide target buy prices or price alerts. However, our 11 active models produce fair value estimates ranging from $1.05 to $80.71. At $35.03, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for PAHC.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad